Cargando…
Targeting ferroptosis as a promising therapeutic strategy to treat cardiomyopathy
Cardiomyopathies are a clinically heterogeneous group of cardiac diseases characterized by heart muscle damage, resulting in myocardium disorders, diminished cardiac function, heart failure, and even sudden cardiac death. The molecular mechanisms underlying the damage to cardiomyocytes remain unclea...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10150641/ https://www.ncbi.nlm.nih.gov/pubmed/37138856 http://dx.doi.org/10.3389/fphar.2023.1146651 |
_version_ | 1785035392677838848 |
---|---|
author | Sun, Huiyan Chen, Dandan Xin, Wenjing Ren, Lixue LI, Qiang Han, Xuchen |
author_facet | Sun, Huiyan Chen, Dandan Xin, Wenjing Ren, Lixue LI, Qiang Han, Xuchen |
author_sort | Sun, Huiyan |
collection | PubMed |
description | Cardiomyopathies are a clinically heterogeneous group of cardiac diseases characterized by heart muscle damage, resulting in myocardium disorders, diminished cardiac function, heart failure, and even sudden cardiac death. The molecular mechanisms underlying the damage to cardiomyocytes remain unclear. Emerging studies have demonstrated that ferroptosis, an iron-dependent non-apoptotic regulated form of cell death characterized by iron dyshomeostasis and lipid peroxidation, contributes to the development of ischemic cardiomyopathy, diabetic cardiomyopathy, doxorubicin-induced cardiomyopathy, and septic cardiomyopathy. Numerous compounds have exerted potential therapeutic effects on cardiomyopathies by inhibiting ferroptosis. In this review, we summarize the core mechanism by which ferroptosis leads to the development of these cardiomyopathies. We emphasize the emerging types of therapeutic compounds that can inhibit ferroptosis and delineate their beneficial effects in treating cardiomyopathies. This review suggests that inhibiting ferroptosis pharmacologically may be a potential therapeutic strategy for cardiomyopathy treatment. |
format | Online Article Text |
id | pubmed-10150641 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-101506412023-05-02 Targeting ferroptosis as a promising therapeutic strategy to treat cardiomyopathy Sun, Huiyan Chen, Dandan Xin, Wenjing Ren, Lixue LI, Qiang Han, Xuchen Front Pharmacol Pharmacology Cardiomyopathies are a clinically heterogeneous group of cardiac diseases characterized by heart muscle damage, resulting in myocardium disorders, diminished cardiac function, heart failure, and even sudden cardiac death. The molecular mechanisms underlying the damage to cardiomyocytes remain unclear. Emerging studies have demonstrated that ferroptosis, an iron-dependent non-apoptotic regulated form of cell death characterized by iron dyshomeostasis and lipid peroxidation, contributes to the development of ischemic cardiomyopathy, diabetic cardiomyopathy, doxorubicin-induced cardiomyopathy, and septic cardiomyopathy. Numerous compounds have exerted potential therapeutic effects on cardiomyopathies by inhibiting ferroptosis. In this review, we summarize the core mechanism by which ferroptosis leads to the development of these cardiomyopathies. We emphasize the emerging types of therapeutic compounds that can inhibit ferroptosis and delineate their beneficial effects in treating cardiomyopathies. This review suggests that inhibiting ferroptosis pharmacologically may be a potential therapeutic strategy for cardiomyopathy treatment. Frontiers Media S.A. 2023-04-13 /pmc/articles/PMC10150641/ /pubmed/37138856 http://dx.doi.org/10.3389/fphar.2023.1146651 Text en Copyright © 2023 Sun, Chen, Xin, Ren, LI and Han. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Pharmacology Sun, Huiyan Chen, Dandan Xin, Wenjing Ren, Lixue LI, Qiang Han, Xuchen Targeting ferroptosis as a promising therapeutic strategy to treat cardiomyopathy |
title | Targeting ferroptosis as a promising therapeutic strategy to treat cardiomyopathy |
title_full | Targeting ferroptosis as a promising therapeutic strategy to treat cardiomyopathy |
title_fullStr | Targeting ferroptosis as a promising therapeutic strategy to treat cardiomyopathy |
title_full_unstemmed | Targeting ferroptosis as a promising therapeutic strategy to treat cardiomyopathy |
title_short | Targeting ferroptosis as a promising therapeutic strategy to treat cardiomyopathy |
title_sort | targeting ferroptosis as a promising therapeutic strategy to treat cardiomyopathy |
topic | Pharmacology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10150641/ https://www.ncbi.nlm.nih.gov/pubmed/37138856 http://dx.doi.org/10.3389/fphar.2023.1146651 |
work_keys_str_mv | AT sunhuiyan targetingferroptosisasapromisingtherapeuticstrategytotreatcardiomyopathy AT chendandan targetingferroptosisasapromisingtherapeuticstrategytotreatcardiomyopathy AT xinwenjing targetingferroptosisasapromisingtherapeuticstrategytotreatcardiomyopathy AT renlixue targetingferroptosisasapromisingtherapeuticstrategytotreatcardiomyopathy AT liqiang targetingferroptosisasapromisingtherapeuticstrategytotreatcardiomyopathy AT hanxuchen targetingferroptosisasapromisingtherapeuticstrategytotreatcardiomyopathy |